Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junlan Yang

Showing results (41-50 of 62) with videos related to

Pageof 7
Sort By:
Oncology Letters|January 21, 2017
Ubiquitin specific protease 21 upregulation in breast cancer promotes cell tumorigenic capability and is associated with the NOD-like receptor signaling pathwayLiang Peng, Yi Hu, Demeng Chen, et al.
Journal of Environmental Management|October 1, 2023
Dynamic characteristics of net anthropogenic phosphorus input to the upper Yangtze River Basin from 1989 to 2019: Focus on the phosphate ore rich area in ChinaJunlan Yang, Min Li, Lu Liu, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|November 11, 2016
GINS2 regulates matrix metallopeptidase 9 expression and cancer stem cell property in human triple negative Breast cancerLiang Peng, Zhigang Song, Demeng Chen, et al.
Medicine|July 2, 2015
Epidemiological and Clinicopathological Trends of Breast Cancer in Chinese Patients During 1993 to 2013: A Retrospective StudyWen Si, Ying Li, Yingjie Han, et al.
Breast Cancer Research : BCR|July 25, 2014
Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel aloneBinghe Xu, Zhongzhen Guan, Zhenzhou Shen, et al.
Experimental & Molecular Medicine|April 22, 2017
Inhibition of glutathione metabolism attenuates esophageal cancer progressionLiang Peng, Ruixia Linghu, Demeng Chen, et al.
Medicine|October 16, 2015
Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Retrospective StudyJinyu Li, Junhao You, Wen Si, et al.
Oncology Reports|October 22, 2014
Specific growth inhibition of ErbB2‑expressing human breast cancer cells by genetically modified NK‑92 cellsHui Liu, Bo Yang, Tingting Sun, et al.
Oncoimmunology|May 8, 2015
Combating HER2-overexpressing breast cancer through induction of calreticulin exposure by Tras-Permut CrossMabFan Zhang, Jie Zhang, Moyan Liu, et al.
Journal of Hematology & Oncology|August 13, 2016
Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patientsPin Zhang, Zhongsheng Tong, Fuguo Tian, et al.
Pageof 7

Showing results (41-50 of 62) with videos related to

Sort By:
Pageof 7
Oncology Letters|January 21, 2017
Ubiquitin specific protease 21 upregulation in breast cancer promotes cell tumorigenic capability and is associated with the NOD-like receptor signaling pathwayLiang Peng, Yi Hu, Demeng Chen, et al.
Journal of Environmental Management|October 1, 2023
Dynamic characteristics of net anthropogenic phosphorus input to the upper Yangtze River Basin from 1989 to 2019: Focus on the phosphate ore rich area in ChinaJunlan Yang, Min Li, Lu Liu, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|November 11, 2016
GINS2 regulates matrix metallopeptidase 9 expression and cancer stem cell property in human triple negative Breast cancerLiang Peng, Zhigang Song, Demeng Chen, et al.
Medicine|July 2, 2015
Epidemiological and Clinicopathological Trends of Breast Cancer in Chinese Patients During 1993 to 2013: A Retrospective StudyWen Si, Ying Li, Yingjie Han, et al.
Breast Cancer Research : BCR|July 25, 2014
Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel aloneBinghe Xu, Zhongzhen Guan, Zhenzhou Shen, et al.
Experimental & Molecular Medicine|April 22, 2017
Inhibition of glutathione metabolism attenuates esophageal cancer progressionLiang Peng, Ruixia Linghu, Demeng Chen, et al.
Medicine|October 16, 2015
Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Retrospective StudyJinyu Li, Junhao You, Wen Si, et al.
Oncology Reports|October 22, 2014
Specific growth inhibition of ErbB2‑expressing human breast cancer cells by genetically modified NK‑92 cellsHui Liu, Bo Yang, Tingting Sun, et al.
Oncoimmunology|May 8, 2015
Combating HER2-overexpressing breast cancer through induction of calreticulin exposure by Tras-Permut CrossMabFan Zhang, Jie Zhang, Moyan Liu, et al.
Journal of Hematology & Oncology|August 13, 2016
Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patientsPin Zhang, Zhongsheng Tong, Fuguo Tian, et al.
Pageof 7